Polyphor sharpens ax on staff, shutters failed breast cancer test

Polyphor is closing its failed phase 3 breast cancer clinical trial and planning to lay off staff to lower its costs. The Swiss biotech said its “initial” restructuring will affect 29 positions and it is continuing a strategic assessment.